Matsutoka K, Shoda K, Higuchi Y, Nakayama T, Saito R, Maruyama S
Ann Surg Oncol. 2024; 32(1):333-341.
PMID: 39433719
DOI: 10.1245/s10434-024-16387-2.
Imamura T, Komatsu S, Nishibeppu K, Kiuchi J, Ohashi T, Konishi H
BMC Cancer. 2024; 24(1):907.
PMID: 39069624
PMC: 11283702.
DOI: 10.1186/s12885-024-12676-x.
Omar A, Govan D, Penny C
PLoS One. 2023; 18(8):e0289800.
PMID: 37561735
PMC: 10414600.
DOI: 10.1371/journal.pone.0289800.
Takashima Y, Komatsu S, Ohashi T, Kiuchi J, Nishibeppu K, Kamiya H
Cancer Sci. 2023; 114(7):3027-3040.
PMID: 37190912
PMC: 10323105.
DOI: 10.1111/cas.15830.
Abdulmawjood B, Roma-Rodrigues C, Fernandes A, Baptista P
Cancer Drug Resist. 2022; 2(4):1044-1061.
PMID: 35582281
PMC: 9019201.
DOI: 10.20517/cdr.2019.88.
Depletion of tumor suppressor miRNA-148a in plasma relates to tumor progression and poor outcomes in gastric cancer.
Komatsu S, Imamura T, Kiuchi J, Takashima Y, Kamiya H, Ohashi T
Am J Cancer Res. 2022; 11(12):6133-6146.
PMID: 35018247
PMC: 8727801.
MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review).
Zhou K, Chang Y, Han B, Li R, Wei Y
Exp Ther Med. 2021; 21(5):499.
PMID: 33791008
PMC: 8005665.
DOI: 10.3892/etm.2021.9930.
Liquid biopsy as a perioperative biomarker of digestive tract cancers: review of the literature.
Shoda K, Saito R, Maruyama S, Furuya S, Akaike H, Kawaguchi Y
Surg Today. 2020; 51(6):849-861.
PMID: 32979121
DOI: 10.1007/s00595-020-02148-7.
The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma.
Nomair A, Issa N, Madkour M, Shamseya M
Clin Exp Hepatol. 2020; 6(1):20-27.
PMID: 32166120
PMC: 7062117.
DOI: 10.5114/ceh.2020.93052.
MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients.
El-Ahwany E, Mourad L, Zoheiry M, Abu-Taleb H, Hassan M, Atta R
Arch Med Sci. 2019; 15(6):1454-1461.
PMID: 31749873
PMC: 6855160.
DOI: 10.5114/aoms.2019.86621.
Biomarkers for Stratification in Colorectal Cancer: MicroRNAs.
Fadaka A, Pretorius A, Klein A
Cancer Control. 2019; 26(1):1073274819862784.
PMID: 31431043
PMC: 6704426.
DOI: 10.1177/1073274819862784.
Serum level of miR-142-3p predicts prognostic outcome for colorectal cancer following curative resection.
Gao W, Pang D, Yu S
J Int Med Res. 2019; 47(5):2116-2125.
PMID: 30922137
PMC: 6567755.
DOI: 10.1177/0300060519834815.
Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma.
Kiuchi J, Komatsu S, Imamura T, Nishibeppu K, Shoda K, Arita T
Mol Cancer. 2019; 18(1):2.
PMID: 30609933
PMC: 6320607.
DOI: 10.1186/s12943-018-0929-3.
Low Serum Levels of miR-101 Are Associated with Poor Prognosis of Colorectal Cancer Patients After Curative Resection.
He D, Yue Z, Li G, Chen L, Feng H, Sun J
Med Sci Monit. 2018; 24:7475-7481.
PMID: 30341274
PMC: 6204656.
DOI: 10.12659/MSM.909768.
C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells.
Li S, Shi Q, Yuan L, Qin L, Wang Y, Miao Y
J Exp Clin Cancer Res. 2018; 37(1):51.
PMID: 29523159
PMC: 5845216.
DOI: 10.1186/s13046-018-0698-2.
Low plasma levels of miR-101 are associated with tumor progression in gastric cancer.
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T
Oncotarget. 2018; 8(63):106538-106550.
PMID: 29290969
PMC: 5739754.
DOI: 10.18632/oncotarget.20860.
Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer.
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T
Sci Rep. 2017; 7(1):5708.
PMID: 28720759
PMC: 5515843.
DOI: 10.1038/s41598-017-06137-8.
Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers.
Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S
Int J Mol Sci. 2016; 17(9).
PMID: 27598137
PMC: 5037738.
DOI: 10.3390/ijms17091459.
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T
Oncotarget. 2016; 7(38):62034-62048.
PMID: 27566562
PMC: 5308709.
DOI: 10.18632/oncotarget.11500.
Circulating miR-21 as an independent predictive biomarker for chemoresistance in esophageal squamous cell carcinoma.
Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T
Am J Cancer Res. 2016; 6(7):1511-23.
PMID: 27508093
PMC: 4969400.
